Browse every story filed under this topic, curated from trusted publishers around the world.
At AAN 2026, Xenon Pharmaceuticals announced positive results from the Phase III X-TOLE2 study of azetukalner in focal onset seizures (FOS). The post AAN 2026: Phase III success for azetukalner in focal epilepsy paves approval path …
Read full story →You've seen all articles for #aan.
Check back
soon
for new stories.